IGFBP2 and central nervous system cancer: Since Igfbp2 is known to be upregulated in glioma cells (Zumkeller et al. 1993; Dunlap et al. 2007; Phillips et al. 2016), the reported downregulation in MTLE samples may reflect a relative decrease compared to glioma tissue, rather than true reduction relative to healthy hippocampal levels.